

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicant:</b>	Mark E. Duggan, et al.	US/RO
<b>Attorney Docket No.</b>	21073YP	Authorized Officer: <u>Emily Bernhardt</u>
<b>Filing Date:</b>	October 4, 2004	
<b>For:</b>	INHIBITORS OF AKT ACTIVITY	

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**LETTER**


Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21073YP.

Respectfully submitted,

By: 

Matthew A. Leff  
Registration No. 50,149  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000 – RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-1404

Date: October 4, 2004